PBI Builds Out Marketing, Business Development, and Operational Capabilities to Support Growth Strategy

June 24, 2005

Applied Clinical Trials

Company adds key staff, augments infrastructure, launches new corporate logo, and plans to expand into new clinical research markets.

Seattle, WASHINGTON, JUNE 24, 2005 -- Pacific Biometrics, Inc. (OTC BB: PBME, "PBI") has unveiled a series of enhancements to its marketing and business development programs designed to broaden the Company's customer base, further improve its quality of service, and upgrade the lab's operations.

To date, PBI has typically contracted with major pharmaceutical and diagnostics companies to provide highly specialized testing in the lab's focus areas of cardiovascular disease, diabetes and metabolic syndrome, and arthritis and osteoporosis. PBI plans to grow its business by continuing to provide best-in-class service to this existing client base while also pursuing opportunities in the general lab services market, diversifying the client base with medium-sized pharmaceutical and biotech companies, and leveraging its co-marketing agreement with Quintiles to participate in large-scale and global trials.

Recent initiatives to support this strategy include:

  • Addition of a new Senior Vice President of Operations, with more than 15 years' experience, including time at LabCorp, who will manage lab operations and quality control procedures
  • Hire of a new Controller, with more than 25 years' experience in accounting and controller positions, who will oversee development of effective cost-accounting procedures
  • Installation of a new Laboratory Information System (LIS) to streamline and upgrade the Company's project and data management systems
  • Adoption of a new corporate visual identity to span across all company marketing collateral and advertisements.
  • Increased visibility at industry trade shows, such as the Drug Information Association (DIA) annual meeting, and in industry publications via print advertising and targeted publicity campaigns. Recent publicity for PBI includes articles in Med Ad News, B to B Business, Specialty Pharma, and Biotechnology Healthcare.

"We see significant opportunities in the clinical research space both in specialized testing and in general lab services," said Ron Helm, CEO of PBI. "Our deep expertise in three high-growth fields -- cardiovascular disease, diabetes and metabolic disease, and osteoporosis and arthritis -- along with our well established client relationships with leading pharmaceutical and diagnostic developers and our marketing relationship with Quintiles make us uniquely qualified to pursue these opportunities."

About Pacific Biometrics, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists and through its non-profit affiliate Pacific Biometrics Research Foundation is one of only three U.S.-based laboratories approved and accredited by the Center for Disease Control (CDC) as a Cholesterol Reference Laboratory. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.

For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com or contact Ronald Helm, Chairman / CEO at 206-298-0068.

Related Content:

News